Chemistry, Manufacturing & Controls
Regulatory CMC
The molecule gets the attention. The CMC package gets you approved.
The molecule gets the attention. The CMC package gets you approved.
More programs stall on chemistry, manufacturing, and controls than on efficacy. A specification too tight to pass validation, a process change with no comparability data behind it, a Module 3 that contradicts the batch records: none of these are clinical problems, and all of them can hold a filing. CMC is also unforgiving of timing. What is right for a first-in-human IND is wrong for a commercial NDA, and evidence you failed to collect in Phase 1 cannot be recovered at registration. We build CMC programs that are phase-appropriate at every stage and defensible at the end.
The CMC section decides whether the product can be made at scale, at cost, on time.
CMC is not a set of independent tasks. It is a single narrative that has to hold as the product scales from a few grams in the lab to commercial supply, each stage building the evidence the next one depends on.
Specifications, comparability, and process controls that survive review and inspection — scoped for the post-approval flexibility ICH Q14's established conditions reward.
Decide what to build now and what to defer, before deferring quietly becomes a gap you cannot backfill.
Quality by Design: which attributes matter to the patient, which parameters move them, and how wide the window can be.
Validated methods and specifications you can justify against real batch and stability data, not a handful of lucky lots — including an elemental impurities risk assessment, dose-tiered organic impurity thresholds, and residual solvent limits set on the right calculation reviewers expect to see documented, not just tested.
The control strategy, process validation, and comparability protocol that survive a pre-approval inspection.
Years of work read as one document that has to agree with itself, from 3.2.S through the Quality Overall Summary.
Post-approval change under ICH Q12, so every site, supplier, and process change reaches every market without interrupting supply.
Phase-appropriate is a discipline, and it cuts both ways. The skill is spending exactly enough, exactly when the evidence has to exist, and not a stage sooner.
Characterize and validate a process you are going to change anyway, and you burn cash and time proving something the next scale-up will make obsolete.
Skip the study whose data takes years to mature, and you reach registration with a hole no amount of money can backfill, because the batches are already gone.
Every tank, study, and validation run lands on a milestone. None of it lands a stage too soon.
The lifecycle above holds for most programs. Two situations rewrite it: advanced modalities whose CMC is the hardest part of the whole program, and a manufacturing crisis that does not wait for the roadmap.
For advanced modalities, a change you cannot characterize can be a change to the drug itself.
For a small molecule the structure is defined and the process serves it. For a biologic, a cell therapy, or a gene therapy, the process largely defines the product, so a change you cannot fully characterize can be a change to the drug. Comparability carries far more weight, and potency assays are often the unsolved problem.
A confirmed out-of-specification result on a pivotal batch, a CMC-driven Complete Response Letter, a comparability failure, a 483 that threatens supply: none arrive on schedule. We run remediation under pressure, separating the science problem from the documentation problem, and protect both the filing and the supply chain.
CMC is judged on whether the manufacturing story holds together under scrutiny. Your leads are senior CMC and quality practitioners who have developed processes, authored Module 3, defended comparability, and passed the pre-approval inspections that decide whether a product ships.
We know the difference between phase-appropriate and gold-plated, and we spend your capital like the finite thing it is.
We build the control strategy and validation the way a pre-approval inspection reads it, because that is where CMC packages fail.
Small molecule, biologic, and the cell and gene therapies where the process itself is the product.
We have run CMC remediation under a Complete Response Letter and a supply threat, and kept both the filing and the supply chain intact.
CMC anchors the manufacturing side of a program and feeds the filing. These are the services it most often connects to.
The strategy and the agency meetings that decide what the CMC package actually has to prove, and when.
Explore FDA →Where the drug constituent's CMC meets a device, and 21 CFR Part 4 sets the quality architecture.
Explore Combination →Module 3 assembled, validated, and transmitted through the gateway, consistent across every region.
Explore Publishing →Tell us where the product stands: first IND, mid-phase process change, registration filing, or a post-approval problem that will not wait. We'll match you with a senior CMC lead who has been through that stage and respond within one business day. All inquiries are strictly confidential.
